Business Description
ISIN : US4525253062
Total Employee Number:
73Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.71 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.4 | |||||
Debt-to-EBITDA | 3.42 | |||||
Interest Coverage | 9.71 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 4.4 | |||||
Beneish M-Score | -2.7 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.5 | |||||
3-Year EBITDA Growth Rate | 74 | |||||
3-Year Book Growth Rate | -8.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.35 | |||||
9-Day RSI | 39.1 | |||||
14-Day RSI | 41.4 | |||||
3-1 Month Momentum % | 13.54 | |||||
6-1 Month Momentum % | 71.08 | |||||
12-1 Month Momentum % | 83.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.75 | |||||
Quick Ratio | 2.71 | |||||
Cash Ratio | 2 | |||||
Days Inventory | 179.89 | |||||
Days Sales Outstanding | 33.18 | |||||
Days Payable | 20.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.3 | |||||
Shareholder Yield % | 2.07 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 40.32 | |||||
Operating Margin % | 12.6 | |||||
Net Margin % | 2.57 | |||||
EBITDA Margin % | 11.85 | |||||
FCF Margin % | 13.74 | |||||
OCF Margin % | 19.21 | |||||
ROE % | 2.68 | |||||
ROA % | 1.75 | |||||
ROIC % | 9.69 | |||||
3-Year ROIIC % | -630.67 | |||||
ROC (Joel Greenblatt) % | 3.41 | |||||
ROCE % | 3.05 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 125 | |||||
PE Ratio without NRI | 31.06 | |||||
Price-to-Owner-Earnings | 92.59 | |||||
PS Ratio | 2.96 | |||||
PB Ratio | 2.89 | |||||
Price-to-Tangible-Book | 2.91 | |||||
Price-to-Free-Cash-Flow | 21.65 | |||||
Price-to-Operating-Cash-Flow | 15.48 | |||||
EV-to-EBIT | 75.47 | |||||
EV-to-EBITDA | 25.97 | |||||
EV-to-Revenue | 3.08 | |||||
EV-to-FCF | 22.4 | |||||
Price-to-GF-Value | 1.45 | |||||
Price-to-Projected-FCF | 10.99 | |||||
Price-to-Median-PS-Value | 1.1 | |||||
Price-to-Graham-Number | 2 | |||||
| Price-to-Net-Current-Asset-Value | 15.63 | |||||
Earnings Yield (Greenblatt) % | 1.33 | |||||
FCF Yield % | 4.64 | |||||
Forward Rate of Return (Yacktman) % | 8.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ICCC
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
ImmuCell Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 30.675 | ||
| EPS (TTM) ($) | 0.08 | ||
| Beta | 0.8077 | ||
| 3-Year Sharpe Ratio | 0.66 | ||
| 3-Year Sortino Ratio | 1.23 | ||
| Volatility % | 53.1 | ||
| 14-Day RSI | 41.4 | ||
| 14-Day ATR ($) | 0.45527 | ||
| 20-Day SMA ($) | 10.4125 | ||
| 12-1 Month Momentum % | 83.66 | ||
| 52-Week Range ($) | 4.52 - 12.1 | ||
| Shares Outstanding (Mil) | 9.08 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ImmuCell Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ImmuCell Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 09:00 | In 76 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 75 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 09:00 | 10.90 (-0.55%) | ||
| Second quarter earnings results for 2026 | 2026-08-13 | 10.98 (+1.67%) | ||
| General meeting for 2026 | 2026-06-11 09:30 | 9.67 (-1.28%) | ||
| First quarter earnings conference call for 2026 | 2026-05-15 09:00 | 8.26 (-2.82%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 8.36 (-3.02%) | ||
| Annual report for 2025 | 2026-03-30 | 6.52 (+0.77%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-05 09:00 | 6.46 (+2.38%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-04 | 6.40 (-1.54%) |
ImmuCell Corp Frequently Asked Questions
Guru Commentaries on NAS:ICCC
ImmuCell is a $65mm market cap animal health company whose core franchise is the First Defense line of products, which protect newborn calves against scours, a leading cause of death for young calves. The First Defense products provide an attractive alternative to vaccines and are gaining share in their core market. New management has shifted focus to growing First Defense, eliminating a money-losing product and investing in capacity expansion and sales. The board has been reshaped to increase independence and strategic value, which enhances our optimism about ImmuCell's growth potential and ability to build a broader animal health platform.
ImmuCell’s thesis remains intact following record first quarter results. The highlight of the quarter was the expansion in gross margins to 42%, resulting in record net income and cash flow. Management is targeting further expansion of gross margins to 45% and it appears this is within sight as there hasn’t been a contamination issue since last April and production has been operating at full capacity for two quarters in a row now. I believe that ImmuCell is at a major inflection point, with scours production finally stabilized and the impending FDA approval of Re-Tain, there is a prime opportunity for any talented executive to take over the reigns with a clear path to create immense value for themselves and shareholders in the immediate future.
Press Release
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
